ClinicalTrials.gg
RecruitingNCT07322367Updated Nov 10, 2026

A Mobile Patient Health Technology Intervention for Improving Lung Cancer Screening Rates in Eligible High Risk Patients

An interventional study of Portal Message with Reminder Text Messages and Text Message with Reminder Text Messages in Lung Cancer, sponsored by Wake Forest University Health Sciences. Recruiting at 1 site in United States. Open to participants aged 50 Years to 77 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Wake Forest University Health Sciences · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Nov 10, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
27,000
Allocation
Randomized
Ages
50 Years to 77 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Lung Neoplasms by Wake Forest University Health Sciences — 3 open to participants now, 6 under way, none of them phase 3. Lung Neoplasms · Wake Forest University Health Sciences.

Planned enrollment
Largest of 31
27,000 · median 46
Started
2026
with 1 other
No phase
14 of 36
3 open now
Registered
36th of 36
by date

Among the 36 studies in Lung Neoplasms by Wake Forest University Health Sciences, this one has the largest planned enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2026, is one of 14 with no phase, and was the 36th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

3 of the 36 studies in Lung Neoplasms by Wake Forest University Health Sciences are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 50 Years to 77 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Lung Neoplasms by Wake Forest University Health Sciences, or all of them as a file.
02

Study summary

To evaluate the real-world effectiveness and implementation strategies for mPATH-Lung, investigators propose a pragmatic, randomized controlled trial across an academic Learning Health System. The trial will contrast several approaches to participant outreach and will specifically target engaging fully powered cohorts of racial/ethnic minorities and rural residents.

Read the detailed description

Primary Objective: Evaluate the real-world effectiveness of mPATH-Lung in increasing lung cancer screening rates across diverse populations.

Secondary Objectives

  • Compare the differential effectiveness of three outreach strategies for engaging participants with mPATH-Lung across vulnerable rural or ethnic/racial minority population subgroups.
  • Estimate the additional revenue generated by mPATH-Lung through increased screening and downstream care.
  • Evaluate the potential for over-screening and the impact of applying HEDIS-based exclusion criteria
03

Conditions studied

  • Lung Cancer

Browse trials for

04

Who can participate

Ages eligible
50 Years to 77 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Eligible patients will:

  • Meet the Medicare criteria for lung cancer screening, as updated in February 2022:
  • Age 50 - 77 years
  • Smoked at least 20 pack years
  • Current smoker or quit smoking within the past 15 years
  • Be established with a primary care provider within the Atrium Health Wake Forest Baptist health network (defined as having completed at least 1 primary care appointment in the past 6 months or have completed at least 2 primary care appointments within the past 18 months or being scheduled to see a health network primary care provider within the next 30 days).
  • Have a patient portal account or cellphone number listed in the electronic health record
  • Have a North Carolina address listed in the electronic health record

Exclusion criteria

Exclusion Criteria:

The following patients will be excluded:

  • Patients flagged as needing a language interpreter in the electronic health record for any language other than Spanish (electronic messages and intervention are deliverable in English or Spanish only)
  • Those for whom lung cancer screening would be or may be inappropriate:

electronic health record Prior history of lung cancer electronic health record Chest CT within the last 12 months electronic health record Those meeting the HEDIS COL-E measure exclusion criteria based on significant comorbidities and/or frailty.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
27,000 participants (estimated)

Study arms

  • Experimental
    Arm A

    Patient portal message first followed by up to 3 reminder text messages.

    Other: Portal Message with Reminder Text Messages

  • Experimental
    Arm B

    Text message only with up to 3 reminder text messages.

    Other: Text Message with Reminder Text Messages

  • Experimental
    Arm C

    Portal message only with no reminder messages.

    Other: Portal message only

  • Active comparator
    Usual Care Arm

    Patients receive usual care.

    Other: Usual Care

Interventions

  • OtherPortal Message with Reminder Text Messages

    If the participant has an upcoming scheduled appointment, they will receive a reminder text message 5 days after initial portal message, a final reminder text message a day before their scheduled appointment, and potentially an 'in progress' text message reminder if they start the mPATH-Lung program but do not complete it. If the participant does not have an upcoming scheduled appointment, they will receive a reminder text message 5 days after initial portal message, the final reminder message 8 days after the initial message, and potentially an 'in progress' text message reminder.

  • OtherText Message with Reminder Text Messages

    If the participant has an upcoming scheduled appointment, they will receive a reminder text message 5 days after initial message, a final reminder text message a day before their scheduled appointment, and potentially an 'in progress' text message reminder. If the participant does not have an upcoming scheduled appointment, they will receive a reminder text message 5 days after initial message, the final reminder message 8 days after the initial message, and potentially an 'in progress' text message reminder.

  • OtherPortal message only

    Participant will only receive portal message with no reminder text messages.

  • OtherUsual Care

    Standard of care

06

What researchers measure

Primary outcomes

  1. Number of Participants to Complete Lung Screening CT - Primary Effectiveness

    Completion of the lung screening CT by participants.

    Time frame: 90 days

Secondary outcomes

  1. Number of Participants with Eligibility for Lung Screening

    Reach of the mPATH-Lung platform, defined as the participants who determine their eligibility for lung screening within the mPATH-Lung program within 90 days of the first invitation. Investigators will determine reach overall, within subgroups, and within study arms.

    Time frame: 90 days

  2. Number of Requests for Lung Screening

    Requests for lung screening within the mPATH-Lung program

    Time frame: 90 days

  3. Number of Orders for Lung Screening CT Scans

    Orders for lung screening CT scans for participants in study arms

    Time frame: Within 90 days of randomization

  4. Amount of Revenue Generated

    Revenue (costs) generated from lung cancer screening and follow-up care.

    Time frame: 12 months following completion of screenings

  5. Number of Participants that Represent Over-screening

    Among patients with newly diagnosed lung cancer by lung screening, the participants that represent over-screening, defined as a patient being deemed too ill for potentially curative surgery on blinded chart review.

    Time frame: 90 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jan 2027, 10 months after the start.

Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 10 months is below that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2026
First posted
Jan 7, 2026
StartActual
Mar 25, 2026
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact changed: added b•••@advocatehealth.org. See the current contact
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Contact Study contact changed: added b•••@advocatehealth.org. See the current contact

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07322367
Responsible party
Sponsor
First posted
Jan 7, 2026
Start date
Mar 25, 2026
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Study Coordinator
Contact
Aliza.randazzo@advocatehealth.org
704-355-2000
Brent Heideman, Jr., MD
Contact
brent.heideman@advocatehealth.org
Brent Heideman, Jr., MD
principal investigator · Wake Forest Baptist Comprehensive Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion